AU2001289079A1 - Pharmaceutical compositions for sustained drug delivery - Google Patents
Pharmaceutical compositions for sustained drug deliveryInfo
- Publication number
- AU2001289079A1 AU2001289079A1 AU2001289079A AU8907901A AU2001289079A1 AU 2001289079 A1 AU2001289079 A1 AU 2001289079A1 AU 2001289079 A AU2001289079 A AU 2001289079A AU 8907901 A AU8907901 A AU 8907901A AU 2001289079 A1 AU2001289079 A1 AU 2001289079A1
- Authority
- AU
- Australia
- Prior art keywords
- complexes
- peptide
- pharmaceutical compositions
- drug delivery
- sustained drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
Abstract
Sustained delivery formulations comprising a water-insoluble complex of a peptide and a plurality of ligands are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. Methods of making the complexes of the invention, and methods of these complexes are also disclosed.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23218800P | 2000-09-13 | 2000-09-13 | |
US60/232,188 | 2000-09-13 | ||
PCT/US2001/028691 WO2002022154A2 (en) | 2000-09-13 | 2001-09-13 | Pharmaceutical compositions for sustained drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001289079A1 true AU2001289079A1 (en) | 2002-03-26 |
Family
ID=22872187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001289079A Abandoned AU2001289079A1 (en) | 2000-09-13 | 2001-09-13 | Pharmaceutical compositions for sustained drug delivery |
Country Status (8)
Country | Link |
---|---|
US (2) | US7037889B2 (en) |
EP (1) | EP1320387B1 (en) |
JP (1) | JP2004508411A (en) |
AT (1) | ATE552859T1 (en) |
AU (1) | AU2001289079A1 (en) |
DK (1) | DK1320387T3 (en) |
ES (1) | ES2387537T3 (en) |
WO (1) | WO2002022154A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US7022683B1 (en) | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
ATE552859T1 (en) * | 2000-09-13 | 2012-04-15 | Praecis Pharm Inc | PHARMACEUTICAL FORMULATIONS FOR CONTINUOUS DELIVERY OF PEPTIDES |
US7494669B2 (en) * | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
US6777000B2 (en) * | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
WO2003000156A1 (en) | 2001-06-22 | 2003-01-03 | Southern Biosystems, Inc. | Zero-order prolonged release coaxial implants |
JP2006506321A (en) * | 2002-04-11 | 2006-02-23 | チルドレンズ メディカル センター コーポレーション | Methods for inhibiting increased vascular permeability |
CA2480666C (en) * | 2002-04-11 | 2012-03-06 | Children's Medical Center Corporation | Tnp-470 polymer conjugates and use thereof |
EP1578437A4 (en) | 2002-12-27 | 2006-08-09 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
AU2003303646B2 (en) | 2002-12-31 | 2010-03-04 | Altus Pharmaceuticals Inc. | Human growth hormone crystals and methods for preparing them |
JP2006523609A (en) * | 2002-12-31 | 2006-10-19 | アルタス ファーマシューティカルズ インコーポレイテッド | Protein crystal and ionic polymer complex |
US20040224024A1 (en) * | 2003-04-23 | 2004-11-11 | Massachusetts Institute Of Technology | Controlled drug release formulations containing polyion complexes |
US20060193825A1 (en) * | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
JP2007525507A (en) * | 2004-02-26 | 2007-09-06 | ザ ペン ステイト リサーチ ファンデーション | Combination therapy for the treatment of neoplasms using opioid growth factor receptors |
AU2005218539A1 (en) * | 2004-03-01 | 2005-09-15 | Lumen Therapeutics, Llc | Compositions and methods for treating diseases |
US8128952B2 (en) * | 2005-01-12 | 2012-03-06 | Clemson University Research Foundation | Ligand-mediated controlled drug delivery |
WO2007021970A2 (en) * | 2005-08-15 | 2007-02-22 | Praecis Pharmaceuticals, Inc. | Stable pharmaceutical formulations and methods of use thereof |
CA2634053A1 (en) * | 2005-12-23 | 2007-07-05 | Altus Pharmaceuticals Inc. | Compositions comprising polycation-complexed protein crystals and methods of treatment using them |
US7640223B2 (en) * | 2006-11-16 | 2009-12-29 | University Of Tennessee Research Foundation | Method of organizing and presenting data in a table using stutter peak rule |
JP5305371B2 (en) * | 2007-07-19 | 2013-10-02 | 国立大学法人 岡山大学 | Biomembrane-permeable composition and method for enhancing biomembrane permeability of drugs |
RU2539832C2 (en) | 2008-10-17 | 2015-01-27 | Дана-Фарбер Кэнсер Инститьют, Инк. | Muc-1 protein cytoplasmic domain peptides as cancer inhibitors |
JP5542687B2 (en) | 2008-11-05 | 2014-07-09 | 国立大学法人 東京医科歯科大学 | Hyaluronic acid derivative and pharmaceutical composition thereof |
EP2435062A4 (en) * | 2009-05-27 | 2013-01-02 | Dana Farber Cancer Inst Inc | Inhibition 0f inflammation using antagonists of muc1 |
US8685928B2 (en) | 2010-02-12 | 2014-04-01 | Dana-Farber Cancer Institute, Inc. | Antagonists of MUC1 |
US9044421B2 (en) | 2012-03-28 | 2015-06-02 | Genus Oncology, Llc | Treating MUC1-expressing cancers with combination therapies |
US11564971B2 (en) | 2012-09-05 | 2023-01-31 | Chugai Seiyaku Kabushiki Kaisha | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto |
JP7221211B2 (en) | 2017-11-15 | 2023-02-13 | 中外製薬株式会社 | Hyaluronic Acid Derivatives Modified with Polyethylene Glycol |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1053581A (en) | 1972-09-15 | 1979-05-01 | Carlos M. Samour | Sustained release compositions |
EP0083367A1 (en) | 1981-07-02 | 1983-07-13 | WALTON, Alan G. | Glycosaminoglycan drug complexes |
US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US4980150A (en) | 1989-04-27 | 1990-12-25 | Zetachron, Inc. | Chlorhexidine complex |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5888762A (en) | 1990-06-05 | 1999-03-30 | Centre National De La Recherche Scientifique (Cnrs) | Neurotropic growth factors comprising a homeobox peptide |
ATE164395T1 (en) * | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
EP0593956B1 (en) * | 1992-10-21 | 2002-02-13 | Dade Behring Inc. | Agglutination assays using multivalent ligands |
US5763422A (en) | 1995-01-27 | 1998-06-09 | Board Of Regents, The University Of Texas System | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
US5972326A (en) | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5830883A (en) | 1995-11-06 | 1998-11-03 | Duquesne University Of The Holy Ghost | Methods of creating a unique chitosan and employing the same to form complexes with drugs, delivery of the same within a patient and a related dosage form |
DE19649645A1 (en) * | 1996-11-29 | 1998-06-04 | Hoechst Ag | Multiple functional ligand system for target cell-specific transfer of nucleotide sequences |
US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
DE19712718C2 (en) * | 1997-03-26 | 1999-09-23 | Asta Medica Ag | Immobilized and activity-stabilized complexes of LHRH antagonists and process for their preparation |
US6043024A (en) * | 1997-04-18 | 2000-03-28 | Abbott Laboratories | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
JP2001513987A (en) | 1997-08-22 | 2001-09-11 | ワシントン大学 | Inductive control system and its use |
US6015787A (en) | 1997-11-04 | 2000-01-18 | New England Medical Center Hospitals, Inc. | Cell-permeable protein inhibitors of calpain |
WO1999029721A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
AU1689599A (en) | 1997-12-26 | 1999-07-19 | Toray Industries, Inc. | Sustained release medicinal compositions |
AU2887099A (en) * | 1998-03-06 | 1999-09-20 | Abbott Laboratories | Ligand screening and design by x-ray crystallography |
EP1073763A4 (en) | 1998-04-28 | 2002-08-07 | Univ Washington | Methods for transducing fusion molecules |
AU3347900A (en) * | 1999-01-23 | 2000-08-07 | Minerva Biotechnologies Corporation | Interaction of colloid-immobilized species with species on non-colloidal structures |
GB9912965D0 (en) * | 1999-06-03 | 1999-08-04 | Oxford Biomedica Ltd | In vivo selection method |
ATE552859T1 (en) * | 2000-09-13 | 2012-04-15 | Praecis Pharm Inc | PHARMACEUTICAL FORMULATIONS FOR CONTINUOUS DELIVERY OF PEPTIDES |
AU3940702A (en) * | 2000-11-30 | 2002-06-11 | Penn State Res Found | Dna methyl transferase inhibitors |
-
2001
- 2001-09-13 AT AT01968868T patent/ATE552859T1/en active
- 2001-09-13 WO PCT/US2001/028691 patent/WO2002022154A2/en active Application Filing
- 2001-09-13 EP EP01968868A patent/EP1320387B1/en not_active Expired - Lifetime
- 2001-09-13 JP JP2002526404A patent/JP2004508411A/en active Pending
- 2001-09-13 ES ES01968868T patent/ES2387537T3/en not_active Expired - Lifetime
- 2001-09-13 US US09/953,247 patent/US7037889B2/en not_active Expired - Fee Related
- 2001-09-13 DK DK01968868.8T patent/DK1320387T3/en active
- 2001-09-13 AU AU2001289079A patent/AU2001289079A1/en not_active Abandoned
-
2005
- 2005-06-30 US US11/173,901 patent/US8084419B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2004508411A (en) | 2004-03-18 |
ATE552859T1 (en) | 2012-04-15 |
EP1320387B1 (en) | 2012-04-11 |
EP1320387A2 (en) | 2003-06-25 |
DK1320387T3 (en) | 2012-07-16 |
US20020086829A1 (en) | 2002-07-04 |
US8084419B2 (en) | 2011-12-27 |
US7037889B2 (en) | 2006-05-02 |
WO2002022154A2 (en) | 2002-03-21 |
ES2387537T3 (en) | 2012-09-25 |
US20060094662A1 (en) | 2006-05-04 |
WO2002022154A3 (en) | 2003-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001289079A1 (en) | Pharmaceutical compositions for sustained drug delivery | |
JO1998B1 (en) | Pharmaceutical formulations for sustained drug delivery | |
MXPA02011003A (en) | Stable metal ion lipid powdered pharmaceutical compositions for drug delivery and methods of use. | |
WO2007022254A3 (en) | Pharmaceutical formulations for sustained drug delivery | |
AU2274201A (en) | Compounds and compositions for delivering active agents | |
IL153297A0 (en) | Compounds and compositions for delivering active agents | |
TW200500098A (en) | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery | |
MXPA05007158A (en) | Pharmaceutical formulation with an insoluble active agent for pulmonary administration. | |
DE60121570D1 (en) | ORAL FASCINATING, FIXED PHARMACEUTICAL FORMS TO BE APPLIED ORIGINALLY | |
WO2002074247A8 (en) | Pharmaceutical formulations for sustained release | |
WO2004105694A3 (en) | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | |
IL138767A0 (en) | Anticancer compositions | |
MX2010002409A (en) | Particulate compositions for delivery of poorly soluble drugs. | |
WO2003035051A3 (en) | The use of proton sequestering agents in drug formulations | |
WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
AU3492100A (en) | Oxadiazole compounds and compositions for delivering active agents | |
WO2005025535A3 (en) | Methods for preparing pharmaceutical compositions | |
MXPA03007857A (en) | Compounds and compositions for delivering active agents. | |
EP1279406A4 (en) | Transporters and drug delivery system by using the same | |
TNSN05048A1 (en) | Inhalation compositions with high drug ratios | |
HK1022265A1 (en) | Biodegradable microparticles for the sustained delivery of therapeutic drugs | |
MXPA03002807A (en) | Stabilization of solid drug formulations. | |
WO2004112838A3 (en) | Codrugs of diclofenac | |
CA2585754C (en) | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy | |
AU2003296602A1 (en) | Quaternary compounds comprising propolis as the active substance |